07:00 , Oct 12, 2015 |  BC Week In Review  |  Financial News

OncoResponse completes venture financing

OncoResponse Inc. , Houston, Texas   Business: Cancer, Antibodies   Date completed: 2015-10-06   Type: Venture financing   Raised: $9.5 million   Investors: Arch Development; Canaan Partners; The University of Texas MD Anderson Cancer Center...
07:00 , May 12, 2003 |  BC Week In Review  |  Company News

zuChem board of directors update

zuChem Inc. , Chicago, Ill.   Business: Nutraceuticals, Supply/Service   Appointed: Thomas Churchwell, managing partner of Arch Development Partners; and Douglas Stewart, regional president of National City Bank  ...
07:00 , Jul 9, 2001 |  BC Week In Review  |  Company News

Aviron, University of Chicago news

The U.S. Court of Appeals for the Federal Circuit upheld a lower court decision to drop charges of unjust enrichment and all other tort claims against Aviron brought by Joany Chou, a former graduate student...
08:00 , Oct 30, 2000 |  BC Week In Review  |  Clinical News

Epstein-Barr virus (EBV) vaccine: Began Phase II trial

Aviron (AVIR), Mountain View, Calif.   Product: Epstein-Barr virus (EBV) vaccine   Business: Infectious diseases   Therapeutic category: Immune stimulation   Target: Immune cells   Description: EBV surface antigen combined with adjuvant from SmithKline Beecham...
08:00 , Nov 10, 1997 |  BioCentury  |  Emerging Company Profile

Idun Pharmaceuticals Inc.

Idun Pharmaceuticals Inc. La Jolla, Calif. Technology: Small molecules that regulate cell death (apoptosis) Disease focus: Stroke and neurodegenerative diseases, cancer, organ damage Clinical status: Preclinical Founded: 1993 by Lawrence Fritz, Kevin Tomaselli, Costa Sevastopoulos,...
07:00 , Oct 10, 1994 |  BC Week In Review  |  Clinical News

Avid Therapeutics regulatory update

The Philadelphia company received two U.S. Patents covering its technologies for discovering drugs targeted at hepatitis B and herpes. Patent No. 5,334,524, licensed by Avid from the Fox Chase Cancer Center, covers a composition of...
07:00 , Sep 26, 1994 |  BC Week In Review  |  Company News

Hyseq Inc. deal

Hyseq received exclusive worldwide patent rights from the University of Chicago's ARCH Development Corp. to a biochemical chip that the Sunnyvale, Calif., company said can decipher the human genome many times faster than conventional means....
07:00 , Aug 8, 1994 |  BioCentury  |  Strategy

Getting real about competition

Getting real about competition Competition is nice, but overly fragmented technology and too many companies competing for a limited pool of funds in a single area can make it hard to get anything done. A...
07:00 , Jul 18, 1994 |  BC Week In Review  |  Clinical News

Aviron regulatory update

Aviron   Aviron and the University of Chicago's techology transfer arm, ARCH Development Corp., received U.S. Patent No. 5,328,688 covering genetically engineered herpes simplex viruses (HSV) that may be useful as vaccines to prevent HSV...
07:00 , Jul 11, 1994 |  BC Week In Review  |  Company News

Avid Therapeutics deal

Philadelphia-based Avid received an exclusive worldwide license to molecular targets involving the herpes family of viruses from ARCH Development Corp., the technology licensing affiliate of the University of Chicago. The licensed targets are the herpes...